In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the ...
AI tools have emerged as a transformative technology to help spot or avert any potential disruptions in the global ...
Based on research and analysis of the global microecology market, as well as the evaluation of relevant companies in the ...
Despite negative equity, Amneal raised its operating cash flow guidance for FY25. Read why I agree with Wall St., which is ...
CCL Industries is analyzed through its business segments, acquisition strategy, and competitive positioning. Read why CCLLF ...
A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...
Patients in the ratutrelvir arm received ratutrelvir 600 mg orally once daily for 10 days, while patients in the comparator ...
For one, interest rates are finally going down, with the Federal Reserve executing its latest cut on December 10. And ...
Advances in genetic and molecular profiling can enable more personalized treatment approaches, improving outcomes and ...
NetraMark Holdings Inc. (the 'Company” or 'NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered ...
In 2023, Japan's market size for Paroxysmal Nocturnal Hemoglobinuria therapeutics was around USD 88.5 million, with expectations of growth throughout the forecast period (2024-2034). Projections ...
Companies say the EU’s deregulation efforts are insufficient against Trump's “carrot-and-stick” strategy of pairing generous US tax incentives with a punitive 15% tariff on imports from the EU.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback